05/24/22 9:57 PMNasdaq : KDNY offeringChinook Therapeutics Announces Pricing of a $105 Million Public OfferingChinook Therapeutics, Inc. (Nasdaq: KDNY) today announced the pricing of its underwritten public offering of 6,428,572 shares of its common stock at a price to the public of $14.00 per share. In addition, and in lieu of common stock, Chinook is offeringRHEA-AIneutral
05/24/22 4:02 PMNasdaq : KDNY offeringChinook Therapeutics Announces Proposed Public OfferingChinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that it has commenced an underwritten public offering of itsRHEA-AIneutral
05/20/22 10:25 AMNasdaq : KDNY clinical trialChinook Therapeutics Presents Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort and Evotec Collaboration at the 59th European Renal Association (ERA) Congress 2022The AFFINITY IgAN cohort of 20 patients is fully enrolled, with 70% of patients in the study having baseline proteinuria over one gram per day despite maximal RAS inhibitor treatment, representing an IgAN patient population at high risk for progression Atrasentan was well-tolerated with noRHEA-AIneutral
05/19/22 2:05 AMNasdaq : KDNY clinical trialChinook Therapeutics Presents Updated Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and from Atrasentan Preclinical Mechanism of Action Studies at the 59th European Renal Association (ERA) Congress 2022All patients with IgAN in Cohort 1 have transitioned to subcutaneous (SC) dosing, and BION-1301 remains well-tolerated, with no serious adverse events (SAEs) and no treatment discontinuations due to adverse events (AEs) BION-1301 continues to demonstrate rapid and sustained reductions inRHEA-AInegative
05/12/22 4:20 PMNasdaq : KDNY Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the Compensation Committee of the Company’s Board ofRHEA-AIvery positive
05/12/22 4:00 PMNasdaq : KDNY earningsChinook Therapeutics Provides Business Update and Reports First Quarter 2022 Financial ResultsChinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today provided a business update and reported financial results for the firstRHEA-AIneutral
05/02/22 10:25 AMNasdaq : KDNY conferencesChinook Therapeutics Announces Upcoming Data Presentations and Investor Conference Call at the 59th European Renal Association (ERA) CongressData on atrasentan to be presented in an oral presentation from the IgA nephropathy (IgAN) patient cohort of the phase 2 AFFINITY basket trial Updated data to be presented from Cohort 1 of Part 3 of the ongoing phase 1/2 study of BION-1301 in patients with IgAN Additional abstracts to be presentedRHEA-AIneutral
04/25/22 4:05 PMNasdaq : KDNY conferencesChinook Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor ConferenceChinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to present andRHEA-AIneutral
04/12/22 8:00 AMNasdaq : KDNY clinical trialChinook Therapeutics Announces Initiation of Phase 1 Healthy Volunteer Trial of CHK-336, a First-in-Class LDHA Inhibitor to Treat HyperoxaluriasChinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that dosing has been initiated in a phase 1 clinical trialRHEA-AIneutral
04/05/22 4:05 PMNasdaq : KDNY conferencesChinook Therapeutics to Present at the 21st Annual Needham Virtual Healthcare ConferenceChinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Eric Dobmeier, president and chief executive officer ofRHEA-AIneutral